GoodRx is joining forces with drugmaker Boehringer Ingelheim to make its Humira biosimilar adalimumab available at an affordable price. The pharmaceutical company will offer citrate-free ...
Boehringer Ingelheim and GoodRx are launching a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price available ...
Adalimumab, sold under the brand name Humira, enjoyed a long run as one of the world's best-selling medicines. But its 20-year, competition-free period has ended, and despite its best efforts to delay ...
GoodRx (NASDAQ:GDRX) and Boehringer Ingelheim on Thursday announced an initiative to launch the German drugmaker’s biosimilar against AbbVie’s (NYSE:ABBV) Humira (adalimumab) at an exclusively low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results